Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.
2.

Aggretin Venom Polypeptide as a Novel Anti-angiogenesis Agent by Targeting Integrin alpha2beta1.

Chung CH, Chang CH, Hsu CC, Lin KT, Peng HC, Huang TF.

Sci Rep. 2017 Mar 2;7:43612. doi: 10.1038/srep43612.

3.

Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis.

Wang J, Zhu C.

Onco Targets Ther. 2016 Jul 29;9:4737-46. doi: 10.2147/OTT.S103184. eCollection 2016. Review.

4.

Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants.

Qureshi W, Ali Z, Amjad W, Alirhayim Z, Farooq H, Qadir S, Khalid F, Al-Mallah MH.

Front Cardiovasc Med. 2016 Jul 28;3:24. doi: 10.3389/fcvm.2016.00024. eCollection 2016. Review.

5.

Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis.

Grande R, Natoli C, Ciancola F, Gemma D, Pellegrino A, Pavese I, Garufi C, Di Lauro L, Corsi D, Signorelli D, Sperduti I, Cortese G, Risi E, Morano F, Sergi D, Signorelli C, Ruggeri EM, Zampa G, Russano M, Gamucci T.

PLoS One. 2016 Jul 21;11(7):e0157751. doi: 10.1371/journal.pone.0157751. eCollection 2016.

6.
7.

A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.

Maurea N, Spallarossa P, Cadeddu C, Madonna R, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Tocchetti CG, Zito C, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S93-S104. doi: 10.2459/JCM.0000000000000383.

8.

Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.

Lai XX, Xu RA, Yu-Ping L, Yang H.

Onco Targets Ther. 2016 Apr 21;9:2421-8. doi: 10.2147/OTT.S96156. eCollection 2016.

9.

Cardiotoxicity associated with targeted cancer therapies.

Chen ZI, Ai DI.

Mol Clin Oncol. 2016 May;4(5):675-681. Epub 2016 Mar 3.

10.

Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword.

Liu KL, Chen JS, Chen SC, Chu PH.

Acta Cardiol Sin. 2013 Jul;29(4):295-303. Review.

11.

Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.

Moudgil R, Yeh ET.

Can J Cardiol. 2016 Jul;32(7):863-870.e5. doi: 10.1016/j.cjca.2016.01.027. Epub 2016 Feb 2. Review.

PMID:
27117975
12.

Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives.

McClung EC, Wenham RM.

Int J Womens Health. 2016 Mar 15;8:59-75. doi: 10.2147/IJWH.S78101. eCollection 2016. Review.

13.

Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, Toutouzas K, Leesar MA, Grines CL, Marmagkiolis K.

Circulation. 2016 Mar 29;133(13):1272-89. doi: 10.1161/CIRCULATIONAHA.115.018347. Review.

14.

The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells.

Arnott C, Punnia-Moorthy G, Tan J, Sadeghipour S, Bursill C, Patel S.

PLoS One. 2016 Mar 9;11(3):e0150688. doi: 10.1371/journal.pone.0150688. eCollection 2016.

15.

Bevacizumab for glioblastoma.

Narita Y.

Ther Clin Risk Manag. 2015 Dec 1;11:1759-65. doi: 10.2147/TCRM.S58289. eCollection 2015. Review.

16.

The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents.

Tully CM, Apolo AB, Zabor EC, Regazzi AM, Ostrovnaya I, Furberg HF, Rosenberg JE, Bajorin DF.

Cancer. 2016 Mar 1;122(5):712-21. doi: 10.1002/cncr.29801. Epub 2015 Nov 30.

17.

The Crossroads of Geriatric Cardiology and Cardio-Oncology.

Nguyen KL, Alrezk R, Mansourian PG, Naeim A, Rettig MB, Lee CC.

Curr Geriatr Rep. 2015;4(4):327-337. Epub 2015 Sep 16. Review.

18.

Venous thromboembolism and lung cancer: a review.

Vitale C, D'Amato M, CalabrĂ² P, Stanziola AA, Mormile M, Molino A.

Multidiscip Respir Med. 2015 Sep 15;10(1):28. doi: 10.1186/s40248-015-0021-4. eCollection 2015. Review.

19.

Stroke and Cancer- A Complicated Relationship.

Dearborn JL, Urrutia VC, Zeiler SR.

J Neurol Transl Neurosci. 2014;2(1):1039.

20.

Cancer therapy and cardiovascular risk: focus on bevacizumab.

Economopoulou P, Kotsakis A, Kapiris I, Kentepozidis N.

Cancer Manag Res. 2015 Jun 3;7:133-43. doi: 10.2147/CMAR.S77400. eCollection 2015. Review.

Supplemental Content

Support Center